SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893679917> ?p ?o ?g. }

Showing items 1 to 100 of ±217 with 100 items per page.

W2893679917 endingPage "1097" @default.
W2893679917 startingPage "1083" @default.
W2893679917 abstract "BackgroundUnderstanding how prevalence, incidence, and mortality of motor neuron diseases change over time and by location is crucial for understanding the causes of these disorders and for health-care planning. Our aim was to produce estimates of incidence, prevalence, and disability-adjusted life-years (DALYs) for motor neuron diseases for 195 countries and territories from 1990 to 2016 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016.MethodsThe motor neuron diseases included in this study were amyotrophic lateral sclerosis, spinal muscular atrophy, hereditary spastic paraplegia, primary lateral sclerosis, progressive muscular atrophy, and pseudobulbar palsy. Incidence, prevalence, and DALYs were estimated using a Bayesian meta-regression model. We analysed 14 165 site-years of vital registration cause of death data using the GBD 2016 cause of death ensemble model. The 84 risk factors quantified in GBD 2016 were tested for an association with incidence or death from motor neuron diseases. We also explored the relationship between Socio-demographic Index (SDI; a compound measure of income per capita, education, and fertility) and age-standardised DALYs of motor neuron diseases.FindingsIn 2016, globally, 330 918 (95% uncertainty interval [UI] 299 522–367 254) individuals had a motor neuron disease. Motor neuron diseases have caused 926 090 (881 566–961 758) DALYs and 34 325 (33 051–35 364) deaths in 2016. The worldwide all-age prevalence was 4·5 (4·1–5·0) per 100 000 people, with an increase in age-standardised prevalence of 4·5% (3·4–5·7) over the study period. The all-age incidence was 0·78 (95% UI 0·71–0·86) per 100 000 person-years. No risk factor analysed in GBD showed an association with motor neuron disease incidence. The largest age-standardised prevalence was in high SDI regions: high-income North America (16·8, 95% UI 15·8–16·9), Australasia (14·7, 13·5–16·1), and western Europe (12·9, 11·7–14·1). However, the prevalence and incidence were lower than expected based on SDI in high-income Asia Pacific.InterpretationMotor neuron diseases have low prevalence and incidence, but cause severe disability with a high fatality rate. Incidence of motor neuron diseases has geographical heterogeneity, which is not explained by any risk factors quantified in GBD, suggesting other unmeasured risk factors might have a role. Between 1990 and 2016, the burden of motor neuron diseases has increased substantially. The estimates presented here, as well as future estimates based on data from a greater number of countries, will be important in the planning of services for people with motor neuron diseases worldwide.FundingBill & Melinda Gates Foundation. Understanding how prevalence, incidence, and mortality of motor neuron diseases change over time and by location is crucial for understanding the causes of these disorders and for health-care planning. Our aim was to produce estimates of incidence, prevalence, and disability-adjusted life-years (DALYs) for motor neuron diseases for 195 countries and territories from 1990 to 2016 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016. The motor neuron diseases included in this study were amyotrophic lateral sclerosis, spinal muscular atrophy, hereditary spastic paraplegia, primary lateral sclerosis, progressive muscular atrophy, and pseudobulbar palsy. Incidence, prevalence, and DALYs were estimated using a Bayesian meta-regression model. We analysed 14 165 site-years of vital registration cause of death data using the GBD 2016 cause of death ensemble model. The 84 risk factors quantified in GBD 2016 were tested for an association with incidence or death from motor neuron diseases. We also explored the relationship between Socio-demographic Index (SDI; a compound measure of income per capita, education, and fertility) and age-standardised DALYs of motor neuron diseases. In 2016, globally, 330 918 (95% uncertainty interval [UI] 299 522–367 254) individuals had a motor neuron disease. Motor neuron diseases have caused 926 090 (881 566–961 758) DALYs and 34 325 (33 051–35 364) deaths in 2016. The worldwide all-age prevalence was 4·5 (4·1–5·0) per 100 000 people, with an increase in age-standardised prevalence of 4·5% (3·4–5·7) over the study period. The all-age incidence was 0·78 (95% UI 0·71–0·86) per 100 000 person-years. No risk factor analysed in GBD showed an association with motor neuron disease incidence. The largest age-standardised prevalence was in high SDI regions: high-income North America (16·8, 95% UI 15·8–16·9), Australasia (14·7, 13·5–16·1), and western Europe (12·9, 11·7–14·1). However, the prevalence and incidence were lower than expected based on SDI in high-income Asia Pacific. Motor neuron diseases have low prevalence and incidence, but cause severe disability with a high fatality rate. Incidence of motor neuron diseases has geographical heterogeneity, which is not explained by any risk factors quantified in GBD, suggesting other unmeasured risk factors might have a role. Between 1990 and 2016, the burden of motor neuron diseases has increased substantially. The estimates presented here, as well as future estimates based on data from a greater number of countries, will be important in the planning of services for people with motor neuron diseases worldwide." @default.
W2893679917 created "2018-10-05" @default.
W2893679917 creator A5000455612 @default.
W2893679917 creator A5000525778 @default.
W2893679917 creator A5003956314 @default.
W2893679917 creator A5004128917 @default.
W2893679917 creator A5004515522 @default.
W2893679917 creator A5007119101 @default.
W2893679917 creator A5007642514 @default.
W2893679917 creator A5007918584 @default.
W2893679917 creator A5008989080 @default.
W2893679917 creator A5009474972 @default.
W2893679917 creator A5014730538 @default.
W2893679917 creator A5019194539 @default.
W2893679917 creator A5025222218 @default.
W2893679917 creator A5025988070 @default.
W2893679917 creator A5030995229 @default.
W2893679917 creator A5031889135 @default.
W2893679917 creator A5031904244 @default.
W2893679917 creator A5032372576 @default.
W2893679917 creator A5033169343 @default.
W2893679917 creator A5034485284 @default.
W2893679917 creator A5035870050 @default.
W2893679917 creator A5036537174 @default.
W2893679917 creator A5038100591 @default.
W2893679917 creator A5041157469 @default.
W2893679917 creator A5041560781 @default.
W2893679917 creator A5043947876 @default.
W2893679917 creator A5044936149 @default.
W2893679917 creator A5045102220 @default.
W2893679917 creator A5046959234 @default.
W2893679917 creator A5047104019 @default.
W2893679917 creator A5052615582 @default.
W2893679917 creator A5054130946 @default.
W2893679917 creator A5058392597 @default.
W2893679917 creator A5062712287 @default.
W2893679917 creator A5063788821 @default.
W2893679917 creator A5063950788 @default.
W2893679917 creator A5064443807 @default.
W2893679917 creator A5064939188 @default.
W2893679917 creator A5066701800 @default.
W2893679917 creator A5068432922 @default.
W2893679917 creator A5069600979 @default.
W2893679917 creator A5071042803 @default.
W2893679917 creator A5072132777 @default.
W2893679917 creator A5074790160 @default.
W2893679917 creator A5076154181 @default.
W2893679917 creator A5078486897 @default.
W2893679917 creator A5078524654 @default.
W2893679917 creator A5079111023 @default.
W2893679917 creator A5081239829 @default.
W2893679917 creator A5081409858 @default.
W2893679917 creator A5083535850 @default.
W2893679917 creator A5083792010 @default.
W2893679917 creator A5084511527 @default.
W2893679917 creator A5090216489 @default.
W2893679917 date "2018-12-01" @default.
W2893679917 modified "2023-10-14" @default.
W2893679917 title "Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016" @default.
W2893679917 cites W1215506979 @default.
W2893679917 cites W1906541786 @default.
W2893679917 cites W1964177214 @default.
W2893679917 cites W1986744510 @default.
W2893679917 cites W1993018817 @default.
W2893679917 cites W2001432662 @default.
W2893679917 cites W2007068311 @default.
W2893679917 cites W2011788491 @default.
W2893679917 cites W2020279151 @default.
W2893679917 cites W2037630249 @default.
W2893679917 cites W2044956330 @default.
W2893679917 cites W2072204165 @default.
W2893679917 cites W2084585538 @default.
W2893679917 cites W2088195560 @default.
W2893679917 cites W2105059456 @default.
W2893679917 cites W2131461502 @default.
W2893679917 cites W2134024603 @default.
W2893679917 cites W2150523249 @default.
W2893679917 cites W2154945114 @default.
W2893679917 cites W2157123931 @default.
W2893679917 cites W2158974407 @default.
W2893679917 cites W2162573598 @default.
W2893679917 cites W2170672384 @default.
W2893679917 cites W2173460560 @default.
W2893679917 cites W2336173713 @default.
W2893679917 cites W2336601452 @default.
W2893679917 cites W2520360089 @default.
W2893679917 cites W2606956625 @default.
W2893679917 cites W2733659072 @default.
W2893679917 cites W2743318307 @default.
W2893679917 cites W2753928689 @default.
W2893679917 cites W2765253110 @default.
W2893679917 cites W2790800342 @default.
W2893679917 cites W2801181825 @default.
W2893679917 cites W2802560996 @default.
W2893679917 cites W3025238321 @default.
W2893679917 cites W4211041983 @default.
W2893679917 doi "https://doi.org/10.1016/s1474-4422(18)30404-6" @default.
W2893679917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30409709" @default.